tbuckley/cabot-search huggingface dataset:
Treatment of childhood Hodgkin's disease.
Authors: H Ekert
Journal: Journal of Clinical Oncology (1991)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1991.9.3.528 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 1999723 Treatment of childhood Hodgkin's disease. H EkertxH EkertSearch for articles by this author https://doi.org/10.1200/JCO.1991.9.3.528 PDF "Treatment of childhood Hodgkin's disease.." Journal of Clinical Oncology, 9(3), pp. 528–529© 1991 by American Society of Clinical Oncology
End-Stage Renal Disease After Renal Surgery in Patients with Normal Preoperative Kidney Function: Balancing Surgical Strategy and Individual Disorders at Baseline
Authors: Umberto Capitanio, Alessandro Larcher, Carlo Terrone, Alessandro Antonelli, Alessandro Volpe, Cristian Fiori, Maria Furlan, Federico Dehò, Andrea Minervini, Sergio Serni, Francesco Porpiglia, Francesco Trevisani, Andrea Salonia, Marco Carini, Claudio Simeone, Francesco Montorsi, Roberto Bertini
Journal: European Urology (2016)
Abstract 15520: Incorporating Novel Biomarkers Significantly Improves Risk Stratification for Coronary Heart Disease Patients: the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Trial
Authors: Stefan Blankenberg, Andrew Tonkin, Adrienne Kirby, David M Colquhoun, David Hunt, Anthony C Keech, Paul Nestel, Paul P Glasziou, David R Sullivan, Peter L Thompson, Malcolm West, Harvey D White, Tanja Zeller, Wendy Hague, Kristy Mann, John Simes
Journal: Circulation (2011)
Rxdx-101, an Oral Pan-Trk, Ros1, and Alk Inhibitor, in Patients with Advanced Solid Tumors with Relevant Molecular Alterations
Authors: F.G.M. De Braud, L. Pilla, M. Niger, S. Damian, B. Bardazza, A. Martinetti, G. Pelosi, G. Marrapese, L. Palmeri, G. Cerea, E. Valtorta, S. Veronese, A. Sartore-Bianchi, E. Ardini, M. Martignoni, A. Isacchi, P. Pearson, D. Luo, J.L. Freddo, S. Siena
Journal: Annals of Oncology (2014)
AIDS-related malignant lymphoma: results of prospective treatment trials.
Authors: P S Gill, A M Levine, M Krailo, M U Rarick, C Loureiro, L Deyton, P Meyer, S Rasheed
Journal: Journal of Clinical Oncology (1987)

Twenty-two consecutive patients with high-grade, B-cell lymphomas related to the acquired immunodeficiency syndrome (AIDS) were accrued onto two sequential phase II studies, consisting of a standard regimen (M-BACOD, group no. 1, N = 13), or a novel, intensive regimen (group no. 2, N = 9), which included high-dose cytosine arabinoside (HD-Ara-C), and high-dose methotrexate (HD-MTX), in an attempt to prevent CNS relapse and improve response rates. Stage IV disease was present in 82%. Complete remission (CR) was achieved in seven of 13 patients (54%) in group no. 1, and in three of nine (33%) group no. 2 (P = NS). By multivariate analysis, the most significant factor in predicting response was a Karnofsky performance score (KPS) greater than 60 (P = .04). Three of the ten patients who achieved CR on either regimen have relapsed; in all, five of 13 patients (31%) in group no. 1 have achieved disease-free survival for more than 1 year, compared with one of nine (11%) in group no. 2. CNS progression occurred in six patients in group no. 2, and in two patients in group no. 1. Hematologic toxicity was significantly greater in group no. 2, and these patients had an increased risk of opportunistic infection (one in group no. 1 v seven in group no. 2; P less than .01). Survival was similar, with a median of 11 months in group no. 1 and 6 months in group no. 2. We conclude that the intensive regimen of combination chemotherapy described here is associated with significant risk of early death due to opportunistic infection in patients with AIDS-related lymphoma, and that progression in the CNS remains a major problem. Trials of combination chemotherapy of a less intensive nature, perhaps in combination with immunomodulators or antiretroviral agents should be explored.
The effects of naloxone in chronic schizophrenia
Authors: P A Berger, S J Watson, H Akil, J D Barchas
Journal: American Journal of Psychiatry (1981)

In a placebo-controlled, double-blind crossover study of 14 male chronic schizophrenic patients, high doses of the opiate antagonist naloxone were given intravenously. Hallucinations measured on a verbal-report scale were significantly decreased after naloxone administration. The authors suggest that this apparent action of naloxone is mediated by central opiate receptors and that it may result from an interaction between central endorphin systems and central catecholaminergic neurons.
Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study
Authors: Gary Raskob, Walter Ageno, Alexander T Cohen, Marjolein P A Brekelmans, Michael A Grosso, Annelise Segers, Guy Meyer, Peter Verhamme, Philip S Wells, Min Lin, Shannon M Winters, Jeffrey I Weitz, Harry R Büller
Journal: The Lancet Haematology (2016)
EPID-10GROSS TOTAL RESECTION IS NOT ASSOCIATED WITH IMPROVED OVERALL SURVIVAL RELATIVE TO SUBTOTAL RESECTION IN PATIENTS WITH OLIGODENDROGLIOMAS, ANAPLASTIC OLIGODENDROGLIOMAS, AND OLIGOASTROCYTOMAS
Authors: Xuezhi Dong, Ali Alattar, Jennifer Padwal, Michael Brandel, Bob Carter, Clark Chen
Journal: Neuro-Oncology (2015)

INTRODUCTION: Surgical decisions guiding the resection of primary brain tumors need to be grounded on evidence of benefit. Using the Surveillance, Epidemiology and End Results (SEER) database, we previously demonstrated robust survival difference between patients who underwent gross total resection (GTR) and subtotal resection (STR). Here we provide an analysis of the patient population afflicted with oligodendrogliomas, anaplastic oligodendrogliomas, and oligoastrocytomas. METHODS: In the SEER database (1999-2010), we identified 2,378 low-grade oligodendrogliomas, 1,028 anaplastic oligodendrogliomas (WHO grade III), and 1,505 oligoastrocytomas (all grades). Kaplan-Meier and multivariate Cox regression were used to assess the pattern of surgical practice and overall survival. RESULTS: In contrast to findings reported for anaplastic astrocytoma and glioblastomas, there is little overall survival benefit between low-grade oligodendrogliomas, anaplastic oligodendrogliomas, and oligoastrocytomas patients who underwent GTR relative to STR. The hazard ratio of dying from low-grade oligodendroglioma in patients who underwent GTR relative to STR was 0.948, (CI: 0.709-1.269; p = 0.720). The hazard ratio of dying from anaplastic oligodendroglioma in patients who underwent GTR relative to STR was 0.866, (CI: 0.654-1.148; p = 0.317). The hazard ratio of dying from low-grade oligoastrocytoma in patients who underwent GTR relative to STR was 1.113, (CI: 0.862-1.437; p = 0.413). CONCLUSION: In contrast to patients with anaplastic astrocytoma and glioblastoma, we observed no significant survival benefit of GTR relative to STR in patients afflicted with glial tumors with an oligodendro-component. Surgical consideration should be undertaken in this context.
Angiogenesis Polymorphisms Profile in the Prediction of Clinical Outcome of Advanced Hcc Patients Receiving Sorafenib: Combined Analysis of Vegf and Hif-1. the Alice-2 Study
Authors: L. Faloppi, M. Scartozzi, M. D'Anzeo, M. Bianconi, G. Svegliati Baroni, N. Silvestris, A. Casadei Gardini, G. Masi, R. Giampieri, M. Del Prete, A. Benedetti, S. Cascinu
Journal: Annals of Oncology (2014)
Replication of a distinct psoriatic arthritis risk variant at the<i>IL23R</i>locus
Authors: Ashley Budu-Aggrey, John Bowes, Sabine Loehr, Steffen Uebe, Maria I Zervou, Philip Helliwell, Anthony W Ryan, David Kane, Eleanor Korendowych, Emiliano Giardina, Jonathan Packham, Ross McManus, Oliver FitzGerald, Neil McHugh, Frank Behrens, Harald Burkhardt, Ulrike Huffmeier, Pauline Ho, Javier Martin, Santos Castañeda, George Goulielmos, Andre Reis, Anne Barton
Journal: Annals of the Rheumatic Diseases (2016)

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with the presence of psoriasis. Although the majority of PsA genetic risk loci identified also confer risk for psoriasis, the difference in heritability between the two diseases suggests that there remain uncovered risk loci that are associated with PsA but not psoriasis (herein called PsA-specific loci).1 Here we present an independent replication of a PsA-specific association to rs12044149 at the well-established psoriasis risk locus, IL23R , and confirm its independence of the previously reported psoriasis single-nucleotide polymorphism (SNP); rs9988642.2 ,3

Following quality control, genotype data were available for Spanish, Cretan, German and UK PsA cases (914) and controls (6945), independent of those tested previously2 for rs12044149 and rs9988642. All PsA case subjects were recruited from rheumatology clinics and were diagnosed by a rheumatologist. Genotype data were generated using the Life Technologies TaqMan chemistry on the QuantStudio platform. Data were also available for samples that had been previously genotyped. Case–control association testing was performed separately for …
Abstract 3944: A Case of Supply and Demand: The Cellular Fuel Gauge Controls Regulators of Protein Degradation in the Heart
Authors: Kedryn K Baskin, Heinrich Taegtmeyer
Journal: Circulation (2009)

To preserve its function, the stressed heart activates AMPK. The role of AMPK in the regulation of metabolism and protein synthesis is well established, while it is currently unknown whether AMPK p...
Photopsia during 3-hour paclitaxel administration at doses &gt; or = 250 mg/m2.
Authors: A D Seidman, S Barrett, S Canezo
Journal: Journal of Clinical Oncology (1994)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1994.12.8.1741 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 7913722 Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2. A D SeidmanxA D SeidmanSearch for articles by this author , S BarrettxS BarrettSearch for articles by this author , S CanezoxS CanezoSearch for articles by this author https://doi.org/10.1200/JCO.1994.12.8.1741 PDF "Photopsia during 3-hour paclitaxel administration at doses > or = 250 mg/m2.." Journal of Clinical Oncology, 12(8), pp. 1741–1742© 1994 by American Society of Clinical Oncology
Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma
Authors: Jonathan S. Zager, Jane L. Messina, L. Frank Glass, Vernon K. Sondak
Journal: Journal of the National Comprehensive Cancer Network (2014)

Many unanswered questions remain about what constitutes appropriate guidelines for treatment of Merkel cell carcinoma (MCC). In this review, we address current uncertainty surrounding optimal management of MCC. These areas of uncertainty include early recognition features; clinical and histopathologic prognostic factors; optimum margins of excision of the primary tumor; indications for and value of surgical staging of the clinically negative regional nodes; optimum management of the patient with pathologically positive regional nodes; and indications for and value of radiation to the primary and regional nodes. Through identifying and elaborating on these areas of uncertainty, the authors hope to foster additional research and ultimately improve the evidence base for future iterations of the NCCN Clinical Practice Guidelines in Oncology in this rare but increasingly encountered cutaneous malignancy. The intent, however, is not to exhaustively identify all areas of controversy, but rather to highlight clinically relevant questions that further studies could address to improve the standard of care for MCC.
Response to treatment with antidepressants of patients with severe or moderate nonpsychotic depression and of patients with psychotic depression
Authors: J H Kocsis, J L Croughan, M M Katz, T P Butler, S Secunda, C L Bowden, J M Davis
Journal: American Journal of Psychiatry (1990)

Hospitalized patients were divided into nonpsychotic severely depressed (N = 53), nonpsychotic moderately depressed (N = 54), and psychotic depressed (N = 25) groups and treated with either imipramine or amitriptyline, up to 250 mg/day, for 4 weeks. Good response occurred in 39% of the 38 severely depressed, 67% of the 49 moderately depressed, and 32% of the 19 psychotic depressed patients who completed treatment. The response of the patients with nonpsychotic severe depression did not differ significantly from the response of those with psychotic depression, and both groups fared worse than the group with nonpsychotic moderate depression.
Keep Moving, Your Health Depends On It: Impact of Improved Physical Activity and Weight Loss In a Wellness Program
Authors: Ebenezer Oni, Ehimen Aneni, Maribeth Rouseff, Thinh Tran, Henry Guzman, Sankalp Das, Doris Brown, Joann Santiago-Charles, Teresa Ochoa, Joseph Mora, Cynthia Gilliam, Virginia Lehn, Beatriz Castillo, Lara Roberson, Theodore Feldman, Arthur Agatston, Khurram Nasir
Journal: Circulation (2014)
The Multifaceted Nature of Myelodysplastic Syndromes: Clinical, Molecular, and Biological Prognostic Features
Authors: Peter L Greenberg
Journal: Journal of the National Comprehensive Cancer Network (2013)

The myelodysplastic syndromes (MDS) consist of a heterogeneous spectrum of myeloid clonal hemopathies. The Revised International Prognostic Scoring System (IPSS-R) provides a recently refined method for clinically evaluating the prognosis of patients with MDS. Molecular profiling has recently generated extensive data describing critical hematopoietic molecular and biologic derangements contributing to clinical phenotypes. Current molecular insights have demonstrated roles of specific somatic gene mutations in the development and clinical outcomes of MDS, including their propensity to progress to more aggressive stages, such as acute myeloid leukemia. This article focuses on these recently reported clinical and underlying pathogenetic findings. The discussion provides a synthesis of the prognostic clinical, molecular, and biologic abnormalities intrinsic to the aberrant marrow hematopoietic and microenvironmental influences in MDS.
Patient-Tailored Analysis of Minimal Residual Disease in Acute Myeloid Leukemia Using Next Generation Sequencing
Authors: Erik Malmberg, Sara Ståhlman, Anna Rehammar, Tore Samuelsson, Sofie J Alm, Erik Kristiansson, Jonas Abrahamsson, Hege Garelius, Lars Palmqvist, Linda Fogelstrand
Journal: Blood (2015)
Effects of Age and Sex on Clinical Outcomes After Percutaneous Coronary Intervention Relative to Coronary Artery Bypass Grafting in Patients With Triple-Vessel Coronary Artery Disease
Authors: Kyohei Yamaji, Hiroki Shiomi, Takeshi Morimoto, Kenji Nakatsuma, Toshiaki Toyota, Koh Ono, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Kenji Ando, Shinichi Shirai, Tomoya Onodera, Hirotoshi Watanabe, Masahiro Natsuaki, Ryuzo Sakata, Michiya Hanyu, Noboru Nishiwaki, Tatsuhiko Komiya, Takeshi Kimura
Journal: Circulation (2016)

Age and sex are important considerations in the choice between percutaneous coronary intervention (PCI) and coronary artery bypass grafting (CABG) in daily clinical practice.Of 25 816 patients enrolled in the multicenter Coronary Revascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto; Cohort-1, n=9877; Cohort-2, n=15 939), the present study population consisted of 5651 patients (men, n=3998; women, n=1653) with triple-vessel coronary artery disease who were considered to be pertinent in comparisons of PCI with CABG (PCI, n=3165; CABG, n=2486). Patients were divided into 3 groups according to the tertiles of age: ≤65 years (n=1972), 66 to 73 years (n=1820), and ≥74 years (n=1859). The excess adjusted mortality risk of PCI relative to CABG was significant in patients ≥74 years of age (hazard ratio [HR], 1.40; 95% confidence interval [CI], 1.10-1.79; P=0.006), whereas the risks were neutral in patients ≤65 years of age (HR, 1.05; 95% CI, 0.73-1.53; P=0.78) and in patients 66 to 73 years of age (HR, 1.03; 95% CI, 0.78-1.36; P=0.85; interaction P=0.003). The excess mortality risk of PCI relative to CABG was significant in men (HR, 1.24; 95% CI, 1.03-1.50; P=0.02) and trended to be significant in women (HR, 1.34; 95% CI, 0.98-1.84; P=0.07) without significant interaction between sex and the mortality risk of PCI relative to CABG (interaction P=0.40).There was a significant association between age and the mortality risk of PCI relative to CABG with excess risk in patients ≥74 years of age and neutral risk in younger patients. There was no significant sex-related difference in the mortality risk of PCI relative to CABG.
Side effects and the "blindability" of clinical drug trials
Authors: K White, J Kando, T Park, C Waternaux, W A Brown
Journal: American Journal of Psychiatry (1992)

A novel, simple approach to retrospective assessment of "blindability" was applied to data on outpatients in a controlled, double-blind clinical comparison of a putative antidepressant, etoperidone, and placebo. A "blind" evaluator proved capable of discriminating between the active drug and placebo on the basis of reported side effects alone, raising questions about the true blindness of the study.
Causes of Death Among Long-Term Survivors From Breast Cancer in Connecticut
Authors: Fred Ederer, Sidney J. Cutler, Ira S. Goldenberg, Henry Eisenberg
Journal: JNCI Journal of the National Cancer Institute (1963)

Among 4,100 5-year survivors from breast cancer, 1,456 deaths occurred during a period of follow-up ranging from 5 to 20 years after diagnosis. Mortality was analyzed by the life table method and compared with expected (general population) experience. The ratio of observed-to-expected mortality from breast cancer for the patients who died 5 to 10 years after diagnosis was 40:1. This ratio diminished to 26:1 and 16:1 during the succeeding two 5-year intervals. The observed mortality from cancers other than breast cancer exceeded expectation, though to a far lesser degree, with endometrial and ovarian cancer showing the greatest excess; the mortality ratio for the latter two causes was no greater than 3:1. For each of three noncancer groups of death, i.e., arteriosclerotic heart disease, other cardiovascularrenal diseases, and all other causes, there were fewer deaths than expected.
Lentigo Maligna and Radiotherapy
Authors: Lynn Wilson
Journal: New England Journal of Medicine (2006)

Lentigo Maligna and RadiotherapyTo the Editor: Imiquimod has recently been shown to be effective in the management of lentigo maligna, as demonstrated in Images in Clinical Medicine (Nov.17 issue) 1 and in other reports.The authors correctly suggest that imiquimod may be effective for lentigo maligna, but readers are subsequently led to believe that perhaps this is the only alternative to surgery.Although imiquimod may be a promising nonsurgical alternative for the treatment of lentigo maligna, radiotherapy has been clinically successful, with excellent cosmesis.In one series of 101 patients with either lentigo maligna or lentigo maligna melanoma who were treated with radiotherapy and followed for a minimum of 2 years (mean, 8 years), the mean time to recurrence was 45.6 months, with a recurrence rate of 7 percent. 2Although radiotherapy may not be as convenient as treatment with a self-administered topical agent, it should be recognized as a potential therapeutic choice for patients with lentigo maligna.Radiotherapy can provide excellent cosmesis and local control.
Dual‐Targeting Lactoferrin‐Conjugated Polymerized Magnetic Polydiacetylene‐Assembled Nanocarriers with Self‐Responsive Fluorescence/Magnetic Resonance Imaging for In Vivo Brain Tumor Therapy
Authors: Jen‐Hung Fang, Tsung‐Lang Chiu, Wei‐Chen Huang, Yen‐Ho Lai, Shang‐Hsiu Hu, You‐Yin Chen, San‐Yuan Chen
Journal: Advanced Healthcare Materials (2016)

Maintaining a high concentration of therapeutic agents in the brain is difficult due to the restrictions of the blood–brain barrier (BBB) and rapid removal from blood circulation. To enable controlled drug release and enhance the blood–brain barrier (BBB)‐crossing efficiency for brain tumor therapy, a new dual‐targeting magnetic polydiacetylene nanocarriers (PDNCs) delivery system modified with lactoferrin (Lf) is developed. The PDNCs are synthesized using the ultraviolet (UV) cross‐linkable 10,12‐pentacosadiynoic acid (PCDA) monomers through spontaneous assembling onto the surface of superparamagnetic iron oxide (SPIO) nanoparticles to form micelles‐polymerized structures. The results demonstrate that PDNCs will reduce the drug leakage and further control the drug release, and display self‐responsive fluorescence upon intracellular uptake for cell trafficking and imaging‐guided tumor treatment. The magnetic Lf‐modified PDNCs with magnetic resonance imaging (MRI) and dual‐targeting ability can enhance the transportation of the PDNCs across the BBB for tracking and targeting gliomas. An enhanced therapeutic efficiency can be obtained using Lf‐ Cur (Curcumin)‐PDNCs by improving the retention time of the encapsulated Cur and producing fourfold higher Cur amounts in the brain compared to free Cur . Animal studies also confirm that Lf targeting and controlled release act synergistically to significantly suppress tumors in orthotopic brain‐bearing rats.
A review of salivary gland histopathology in primary Sjögren's syndrome with a focus on its potential as a clinical trials biomarker: Table 1
Authors: Benjamin A Fisher, Rachel M Brown, Simon J Bowman, Francesca Barone
Journal: Annals of the Rheumatic Diseases (2015)

Salivary gland changes, characterised by a focal lymphocytic sialadenitits, play an important role in the diagnosis of primary Sjögren9s syndrome (PSS) and were first described over 40 years ago. Recent evidence suggests that minor salivary gland biopsy may also provide information useful for prognostication and stratification, yet difficulties may arise in the histopathological interpretation and scoring, and evidence exists that reporting is variable. With the increasing number of actual and proposed clinical trials in PSS, we review the evidence that might support the role of histopathology as a biomarker for stratification and response to therapy and highlight areas where further validation work is required.